| http://www.w3.org/ns/prov#value | - The epigenetic modification of chromatin structure for gene regulation suggests that HDAC inhibitors could be therapeutic candidates not only for cancers but also for genetic disorders such as cystic fibrosis, sickle cell anemia, beta-thalassemia, X-linked adrenoleukodystrophy, spinal muscular atrophy, and neurodegenerative disorders, and aging (Kemp S, et al.
|
